Jardiance Does Not Increase Lower Limb Amputation Risk
Empagliflozin (Jardiance) has not been associated with increased risk of lower-extremity amputation and can be safely used in patients with type 2 diabetes and peripheral artery disease (PAD). This distinguishes it from canagliflozin, which carries documented amputation risk.
Evidence Supporting Safety of Empagliflozin
The most definitive evidence comes from the EMPA-REG OUTCOME trial, where empagliflozin actually demonstrated superior limb survival compared to placebo in patients with PAD 1. Among the 1,462 patients (20.8%) with baseline PAD in this trial, empagliflozin showed protective effects rather than harm 1.
Multiple 2024 guidelines explicitly state that no increased risk of amputation has been seen with empagliflozin or dapagliflozin to date 2. The 2024 ACC/AHA PAD guidelines emphasize that concerns about amputation risk are specific to canagliflozin, not a class effect of SGLT2 inhibitors 1.
The Canagliflozin Distinction
The amputation concern originated from the CANVAS trial, where canagliflozin increased amputation risk (6.3 vs 3.4 per 1,000 patient-years; HR 1.97) 1. Most amputations were minor (toe or metatarsal level, 71%) 1. However, the FDA removed the black box warning for canagliflozin in August 2020 after subsequent data from the CREDENCE trial and meta-analyses showed conflicting results 1.
The 2018 ACC Expert Consensus specifically cautioned about amputation risk with canagliflozin and ertugliflozin, but explicitly stated: "No increased risk of amputation has been seen for empagliflozin or dapagliflozin to date" 2.
Patient Evaluation and Management
Pre-Treatment Assessment
Before initiating Jardiance, evaluate for amputation risk factors 1:
- History of prior amputation or foot ulcers
- Severe peripheral vascular disease
- Peripheral neuropathy with loss of protective sensation
- Diabetic foot deformities (Charcot, calluses)
- Poor glycemic control
- Chronic kidney disease, especially ESKD
- Active smoking
Ongoing Monitoring
Perform foot inspection at every clinical visit 1. The 2024 ACC/AHA guidelines recommend:
- Annual comprehensive foot evaluation including assessment of pulses, protective sensation, and skin integrity 1
- Immediate evaluation of any new foot pain, ulcers, or skin changes
- Referral to foot care specialist for patients at high risk 1
Patient Education
Provide verbal and written instructions on:
- Daily foot self-inspection
- Proper footwear (therapeutic footwear for high-risk patients) 1
- Prompt reporting of foot injuries, pain, or skin changes
- Signs of infection requiring urgent evaluation
Clinical Recommendations
Jardiance is recommended for patients with type 2 diabetes and PAD to reduce cardiovascular events 1. The 2024 guidelines give this a Class 1 recommendation based on MACE reduction (10.5% vs 12.1%; p=0.04) and 38% reduction in cardiovascular death 1.
For patients with established PAD and diabetes:
- Empagliflozin or dapagliflozin are preferred SGLT2 inhibitors over canagliflozin if amputation concerns exist 3
- Continue standard preventive foot care regardless of SGLT2 inhibitor choice
- The cardiovascular and renal benefits of empagliflozin outweigh theoretical amputation concerns that have not materialized in clinical trials
Common Pitfalls to Avoid
- Do not withhold empagliflozin due to amputation fears—the evidence does not support this concern for empagliflozin specifically
- Do not assume all SGLT2 inhibitors carry equal amputation risk—this is medication-specific, not a class effect
- Do not neglect baseline foot examination—document baseline status before starting therapy
- Do not skip regular foot surveillance—this is essential for all patients with diabetes and PAD, independent of SGLT2 inhibitor use
The 2022 Canadian Cardiovascular Society guidelines summarize it best: "Presently, there is no reason to suspect that empagliflozin or dapagliflozin increase the risk of PAD or lower limb amputations" 3.